PhaseBio Pharmaceuticals EBT margin

EBT margin of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBT margin growth rates and interactive chart. The Earnings before tax margin. Calculated as earnings before tax divided by revenue. Measures the profitability of a company after all expenses are paid but before taxes. This is useful to compare various companies in an industry that might have different tax regimes or tax rates.


Highlights and Quick Summary

  • EBT margin for the quarter ending June 29, 2021 was -261.94% (a -Infinity% decrease compared to previous quarter)
  • Year-over-year quarterly EBT margin decreased by -Infinity%
  • Annual EBT margin for 2020 was -30801.56% (a 307.64% increase from previous year)
  • Annual EBT margin for 2019 was -7556.0% (a 85.25% increase from previous year)
  • Annual EBT margin for 2018 was -4078.74% (a -Infinity% decrease from previous year)
  • Twelve month EBT margin ending June 29, 2021 was -942.77% (a -Infinity% decrease compared to previous quarter)
  • Twelve month trailing EBT margin decreased by -Infinity% year-over-year
Trailing EBT margin for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
-942.77% 0.0% 0.0% 0.0%
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBT margin of PhaseBio Pharmaceuticals

Most recent EBT marginof PHAS including historical data for past 10 years.

Interactive Chart of EBT margin of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals EBT margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -261.94% 0.0%
2020 0.0% 0.0% 0.0% -4657.81% -30801.56%
2019 -1483.12% -4726.56% -1313.23% -1116.85% -7556.0%
2018 -1894.16% -1922.38% 0.0% 0.0% -4078.74%
2017 0.0% 0.0%
2016 0.0%

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.